Albert Bourla, Pfizer CEO (Efren Landaos/Sipa USA/Sipa via AP Images)
December 14, 2022 03:25 PM EST
Pharma

US set to pay near­ly $2B for Pfiz­er's Covid-19 treat­ment Paxlovid in 2023

Tyler Patchen

News Reporter

The US gov­ern­ment is tee­ing up more Pfiz­er Covid-19 an­tivi­ral pur­chas­es for next year – to the tune of $2 bil­lion.

Pfiz­er’s new agree­ment with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

A service from the Financial Times